Pharmacologic suppression of protein kinase C α (PKCα) can selectively affect breast CSCs and EMT phenotype and that clinically efficient compounds repressing PKCα may confirm curatively helpful for curing special breast cancers [52]. The gene discussed is PRKCA; the disease is breast carcinoma.